Seed funding cluster around proptech, cancer biotech, space tech, robotics; $5M-$10M deals still viable

Crunchbase analysis of ~800 global seed financings in the $5-$10M range in 2026 reveals a bifurcated market: mega-rounds dominate headlines, but modestly-funded bets on unproven founders and moonshot technologies remain viable. Four sectors are clustering: proptech, cancer therapeutics, space/satellite tech, and robotics. Each addresses massive TAMs (real estate is two-thirds of global net worth; cancer affects 39% of Americans) with early-stage companies building efficiencies or novel solutions.

Proptech led the cluster with companies targeting real estate decarbonization, construction supply chains, and rental operations. Standouts include Hint (AI home management), Optiml (building decarbonization), and Krane (construction supply-chain AI). Cancer therapeutics showed strong momentum, with three California startups landing $10M each: Rybodyn (AI-driven cancer target discovery), Vivere Oncotherapies (solid-tumor therapies), and Valius Sciences (cancer diagnostics). Space tech benefited from broader sector enthusiasm post-SpaceX IPO, with Lux Aeterna (reusable satellites), InSpacePropulsion (in-space propulsion), and Constellation Space (satellite operations ML) raising rounds.

Robotics proved the most geographically dispersed sector, with companies from North America, Europe, Asia, and Australia closing seed rounds. Standouts included Somnia Lab (intimacy robotics), Bubble Robotics (autonomous underwater robots), and Eternal.ag (greenhouse harvest automation). The pattern: founders with grand missions and novel tech can still access capital at $5-$10M, even in a landscape dominated by mega-rounds and institutional capital chasing proven founders.

Context: Venture capital allocation has migrated upmarket, with mega-rounds and late-stage deals dominating press coverage and capital deployment. This makes the persistence of modestly-funded seed bets notable. Seed investors appear to believe that venture-scalable solutions to large TAMs still emerge from small, modestly-funded teams—particularly in hardware (robotics, space), biotech, and proptech where capital intensity rises later in the company lifecycle.

For builders in regulated or capital-efficient domains, the lesson is clear: a credible $5-$10M seed round remains achievable if the TAM is large, the problem is acute, and the founder has conviction. Robotics' geographic diversity suggests that non-US seed ecosystems are maturing, reducing venture capital's geographic concentration and allowing more founders global access to capital.